Patents by Inventor Remi Delansorne

Remi Delansorne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer
    Patent number: 10478497
    Abstract: The present invention concerns combinations of inecalcitol with an anti-CD38 agent such as daratumumab, MOR 202 or isatuximab for the treatment of cancer, such as hematological malignancies by increasing or inducing the expression of CD-38 by inecalcitol.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: November 19, 2019
    Assignee: HYBRIGENICS S.A.
    Inventors: Susan Benjamin, Cécile Planquette, Rémi Delansorne
  • COMBINATIONS OF INECALCITOL WITH AN ANTI-CD38 AGENT AND THEIR USES FOR TREATING CANCER
    Publication number: 20180021432
    Abstract: The present invention concerns combinations of inecalcitol with an anti-CD38 agent such as daratumumab, MOR 202 or isatuximab for the treatment of cancer, such as hematological malignancies by increasing or inducing the expression of CD-38 by inecalcitol.
    Type: Application
    Filed: July 20, 2017
    Publication date: January 25, 2018
    Inventors: Susan BENJAMIN, Cécile PLANQUETTE, Rémi DELANSORNE
  • Formulations of 14-epi-analogues of vitamin D
    Patent number: 9314474
    Abstract: The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: April 19, 2016
    Assignee: HYBRIGENICS, SA
    Inventor: Remi Delansorne
  • Cysteine protease inhibitors and their therapeutic applications
    Patent number: 8648076
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.
    Type: Grant
    Filed: July 26, 2006
    Date of Patent: February 11, 2014
    Assignee: Hybrigenics SA
    Inventors: Philippe Guedat, Guillaume Boissy, Catherine Borg-Capra, Frédéric Colland, Laurent Daviet, Etienne Formstecher, Xavier Jacq, Jean-Christophe Rain, Rémi Delansorne, Stefania Vallese, Matteo Colombo
  • Therapeutical uses of inecalcitol
    Patent number: 8481514
    Abstract: The present invention thus concerns a method for treating and/or preventing rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D relevant disease comprising administering inecalcitol at doses comprised between 1 mg/day and 100 mg/day to a human patient in need thereof.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: July 9, 2013
    Assignee: Hybrigenics SA
    Inventors: Rémi Delansorne, Jean-François Dufour-Lamartinie
  • FORMULATIONS OF 14-EPI-ANALOGUES OF VITAMIN D
    Publication number: 20120015915
    Abstract: The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile.
    Type: Application
    Filed: July 13, 2011
    Publication date: January 19, 2012
    Applicant: HYBRIGENICS SA
    Inventor: Remi DELANSORNE
  • Formulations of 14-EPI-Analogues of Vitamin D
    Publication number: 20120015913
    Abstract: The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile.
    Type: Application
    Filed: July 15, 2010
    Publication date: January 19, 2012
    Inventor: Rémi Delansorne
  • FORMULATIONS OF 14-EPI-ANALOGUES OF VITAMIN D
    Publication number: 20120015914
    Abstract: The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile.
    Type: Application
    Filed: July 13, 2011
    Publication date: January 19, 2012
    Applicant: HYBRIGENICS SA
    Inventor: Remi DELANSORNE
  • THERAPEUTICAL USES OF INECALCITOL
    Publication number: 20110015276
    Abstract: The present invention thus concerns a method for treating and/or preventing rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D relevant disease comprising administering inecalcitol at doses comprised between 1 mg/day and 100 mg/day to a human patient in need thereof.
    Type: Application
    Filed: May 18, 2010
    Publication date: January 20, 2011
    Inventors: Rémi DELANSORNE, Jean-François Dufour-Lamartinie
  • NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS
    Publication number: 20090215786
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.
    Type: Application
    Filed: July 26, 2006
    Publication date: August 27, 2009
    Inventors: Philippe Guedat, Guillaume Boissy, Catherine Borg-Capra, Frederic Colland, Laurent Daviet, Etienne Formstecher, Xavier Jacq, Jean-Christophe Rain, Remi Delansorne, Stefania Vallese, Matteo Colombo
  • Novel Inhibitors of Cysteine Proteases, the Pharmaceutical Compositions Thereof and their Therapeutic Applications
    Publication number: 20090181972
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.
    Type: Application
    Filed: December 5, 2006
    Publication date: July 16, 2009
    Inventors: Philippe Guedat, Guillaune Boissy, Catherine Borg-Capra, Frederic Colland, Laurent Daviet, Etienne Formstecher, Xavier Jacq, Jean-Christophe Rain, Remi Delansorne, Ilaria Peretto, Stefano Vignando
  • Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
    Patent number: 7462615
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.
    Type: Grant
    Filed: December 8, 2005
    Date of Patent: December 9, 2008
    Assignee: Hybrigenics SA
    Inventors: Philippe Guedat, Guillaume Boissy, Catherine Borg-Capra, Frédéric Colland, Laurent Daviet, Etienne Formstecher, Xavier Jacq, Jean-Christophe Rain, Rémi Delansorne, Ilaria Peretto, Stefano Vignando
  • Novel inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
    Publication number: 20070135439
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.
    Type: Application
    Filed: December 8, 2005
    Publication date: June 14, 2007
    Inventors: Philippe Guedat, Guillaume Boissy, Catherine Borg-Capra, Frederic Colland, Laurent Daviet, Etienne Formstecher, Xavier Jacq, Jean-Christophe Rain, Remi Delansorne, IIaria Peretto, Stefano Vignando
  • 1-N-phenylamino-1H-imidazole derivatives as aromatase inhibitors and pharmaceutical compositions containing them
    Patent number: 6737433
    Abstract: Imidazole derivatives of the formula: in which R1 and R2 are each independently hydrogen, (C1-C6)alkyl or (C3-C8)cycloalkyl; n is 0, 1 or 2; R3, R4, R5 and R6 are each independently hydrogen or a (C1-C6)alkyl, halogen, cyano, (C1-C6)alkoxy, trifluoromethyl, (C1-C6)alkylthio, (C1-C6)alkylsulfonyl, sulfonamido, acyl, (C1-C6)alkoxycarbonyl, or carboxamido group; R3 and R6 together with the phenyl ring bearing them can also form a benzofurane, or a N-methylbenzotriazole. The invention also relates to pharmaceutical compositions containing these derivatives, and to the uses thereof.
    Type: Grant
    Filed: December 16, 2002
    Date of Patent: May 18, 2004
    Assignee: Laboratoire Theramex
    Inventors: Nathalie Adje, Paule Bonnet, Denis Carniato, Remi Delansorne, Jean Lafay, Jean-Claude Pascal
  • LH-RH peptide analogues, their uses and pharmaceutical compositions containing them
    Patent number: 6586402
    Abstract: The invention relates to LH-RH peptide analogues with excellent affinity for LH-RH receptors, of the formula: A1-A2-A3-A4-A5-A6-HAA-A7-Pro-Z  (I) The invention also relates to the uses of said peptide analogues and to the pharmaceutical compositions containing them.
    Type: Grant
    Filed: November 30, 1999
    Date of Patent: July 1, 2003
    Assignee: Laboratoire Theramex
    Inventors: Rémi Delansorne, Jacques Paris
  • Conformationally constrained LH-RH analogues, their uses and pharmaceutical compositions containing them
    Patent number: 6153587
    Abstract: LH-RH analogues with excellent affinity for LH-RH receptors, of the formula A.sub.1 -A.sub.2 -W-A.sub.3 -A.sub.4 -SPL-A.sub.5 -A.sub.6 -Pro-Z(I) in which:-A.sub.1 is pGlu, AcSar or an aromatic D-amino acid;-A.sub.2 is a direct bond, His, DPhe, DpFPhe or DpClPhe;*W is an aromatic L- or D-amino acid;-A.sub.3 is Ala, Thr, Ser, DSer, Ser(OBzl) or MeSer;-A.sub.4 is Tyr, Phe, cPzACAla, L- or D-PicLys, L- or D-NicLys or L- or D-IprLys;*SPL is the spirolactam of formula: ##STR1## -A.sub.5 is an amino acid with a (C.sub.1 -C.sub.8)alkyl or (C.sub.3-C.sub.6)cycloalkyl side chain;-A.sub.6 is L- or D-(Arg, HArg, Lys, HLys, Orn, Cit, HCit or Aph), where L- or D-(Arg and HArg) can be substituted by one or two (C.sub.1 -C.sub.4)alkyl groups and L- or D-(Lys, HLys, Orn and Aph) can be substituted by an isopropyl, nicotinoyl or picolinoyl group; and*Z is GlyNH.sub.2, DAlaNH.sub.2, AzaGlyNH.sub.2 or --NHR.sub.1 where R.sub.1 is a (C.sub.1 -C.sub.
    Type: Grant
    Filed: May 24, 1999
    Date of Patent: November 28, 2000
    Assignee: Laboratoire THERAMEX
    Inventors: Remi Delansorne, Jacques Paris
  • Derivatives of terbutylphenyl-1-amino-4-hydroxybutane their preparation processes and the pharmaceutical compositions containing them
    Patent number: 5461059
    Type: Grant
    Filed: March 26, 1993
    Date of Patent: October 24, 1995
    Assignee: Laboratoire Theramex S.A.
    Inventors: Paule Bonnet, Remi Delansorne, Maurice Faure, Michel Languetin, Serge Zunino